Kiromic BioPharma Inc, a Houston-based biotherapeutics company, was charged by the SEC for failing to report in its form S-1 and 10-Q filings that the FDA had placed clinical holds on two of its experimental cancer treatments. For their roles in the certifying the deficient filings, former CEO Maurizio Chiriva-Internati
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day